Yeah agree, I think Kinbasha was exceptionally clueless about the OTC market but most of the blame has to fall on their US adviser and Triology who have done a terrible job thus far. Triology is professional, I will give them that but they suck at raising awareness for all the companies they represent, not just Kinbasha. I've run across a couple companies now that I thought were grossly undervalued that use or used Triology at one point.
I'm sure Kinbasha is being told that this level of illiquidty is normal on the OTC QB, thus the reason they are going to the QX and while that may true to a degree, however, they should still be getting at least a little interest given what they have, it's nuts.
It's odd the pachinko industry is sort of seedy, much like US gambling, with ties to the mafia, organized crime and such yet Kinbasha is one of the most legit companies I have run across on the OTC, they approach everything with the utmost transparency and professionalism.
News 
Market Data 
Discover 
